vs
IONIS PHARMACEUTICALS INC（IONS）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
IONIS PHARMACEUTICALS INC的季度营收约是RECURSION PHARMACEUTICALS, INC.的5.7倍（$203.3M vs $35.5M），IONIS PHARMACEUTICALS INC净利率更高（-112.8% vs -304.2%，领先191.4%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs -10.3%），RECURSION PHARMACEUTICALS, INC.自由现金流更多（$-47.3M vs $-159.0M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 30.4%）
IONIS制药是1989年成立的生物科技企业，总部位于美国加利福尼亚州卡尔斯巴德，专注于反义疗法、RNA干扰及CRISPR疗法的研发，2015年12月前曾以Isis制药的名称运营。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
IONS vs RXRX — 直观对比
营收规模更大
IONS
是对方的5.7倍
$35.5M
营收增速更快
RXRX
高出692.0%
-10.3%
净利率更高
IONS
高出191.4%
-304.2%
自由现金流更多
RXRX
多$111.7M
$-159.0M
两年增速更快
RXRX
近两年复合增速
30.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $203.3M | $35.5M |
| 净利润 | $-229.4M | $-108.1M |
| 毛利率 | 96.1% | 59.8% |
| 营业利润率 | -105.5% | -304.8% |
| 净利率 | -112.8% | -304.2% |
| 营收同比 | -10.3% | 681.7% |
| 净利润同比 | -119.8% | 39.6% |
| 每股收益（稀释后） | $-1.35 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IONSRXRX
| Q4 25 | $203.3M | $35.5M | ||
| Q3 25 | $156.7M | $5.2M | ||
| Q2 25 | $452.0M | $19.2M | ||
| Q1 25 | $131.6M | $14.7M | ||
| Q4 24 | $226.6M | $4.5M | ||
| Q3 24 | $133.8M | $26.1M | ||
| Q2 24 | $225.3M | $14.4M | ||
| Q1 24 | $119.5M | $13.8M |
净利润IONSRXRX
| Q4 25 | $-229.4M | $-108.1M | ||
| Q3 25 | $-128.6M | $-162.3M | ||
| Q2 25 | $123.6M | $-171.9M | ||
| Q1 25 | $-146.9M | $-202.5M | ||
| Q4 24 | $-104.3M | $-178.9M | ||
| Q3 24 | $-140.5M | $-95.8M | ||
| Q2 24 | $-66.3M | $-97.5M | ||
| Q1 24 | $-142.8M | $-91.4M |
毛利率IONSRXRX
| Q4 25 | 96.1% | 59.8% | ||
| Q3 25 | 98.5% | -183.8% | ||
| Q2 25 | 99.1% | -4.9% | ||
| Q1 25 | 98.9% | -48.0% | ||
| Q4 24 | 98.3% | -181.4% | ||
| Q3 24 | 99.2% | 53.7% | ||
| Q2 24 | 98.2% | 36.2% | ||
| Q1 24 | 98.2% | 19.1% |
营业利润率IONSRXRX
| Q4 25 | -105.5% | -304.8% | ||
| Q3 25 | -102.2% | -3327.6% | ||
| Q2 25 | 30.9% | -916.8% | ||
| Q1 25 | -111.6% | -1297.9% | ||
| Q4 24 | -48.9% | -4042.4% | ||
| Q3 24 | -111.1% | -377.1% | ||
| Q2 24 | -29.3% | -697.4% | ||
| Q1 24 | -125.1% | -698.4% |
净利率IONSRXRX
| Q4 25 | -112.8% | -304.2% | ||
| Q3 25 | -82.1% | -3135.3% | ||
| Q2 25 | 27.3% | -894.2% | ||
| Q1 25 | -111.6% | -1373.3% | ||
| Q4 24 | -46.1% | -3935.5% | ||
| Q3 24 | -105.0% | -367.5% | ||
| Q2 24 | -29.4% | -676.6% | ||
| Q1 24 | -119.5% | -662.4% |
每股收益（稀释后）IONSRXRX
| Q4 25 | $-1.35 | $-0.17 | ||
| Q3 25 | $-0.80 | $-0.36 | ||
| Q2 25 | $0.70 | $-0.41 | ||
| Q1 25 | $-0.93 | $-0.50 | ||
| Q4 24 | $-0.66 | $-0.56 | ||
| Q3 24 | $-0.95 | $-0.34 | ||
| Q2 24 | $-0.45 | $-0.40 | ||
| Q1 24 | $-0.98 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.7B | $743.3M |
| 总债务越低越好 | $1.8B | $9.6M |
| 股东权益账面价值 | $489.1M | $1.1B |
| 总资产 | $3.5B | $1.5B |
| 负债/权益比越低杠杆越低 | 3.71× | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资IONSRXRX
| Q4 25 | $2.7B | $743.3M | ||
| Q3 25 | $2.2B | $659.8M | ||
| Q2 25 | $2.3B | $525.1M | ||
| Q1 25 | $2.1B | $500.5M | ||
| Q4 24 | $2.3B | $594.4M | ||
| Q3 24 | $2.5B | $427.6M | ||
| Q2 24 | $2.1B | $474.3M | ||
| Q1 24 | $2.2B | $296.3M |
总债务IONSRXRX
| Q4 25 | $1.8B | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | $1.3B | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
股东权益IONSRXRX
| Q4 25 | $489.1M | $1.1B | ||
| Q3 25 | $618.0M | $1.0B | ||
| Q2 25 | $631.7M | $919.1M | ||
| Q1 25 | $475.7M | $933.9M | ||
| Q4 24 | $588.4M | $1.0B | ||
| Q3 24 | $662.5M | $524.6M | ||
| Q2 24 | $263.7M | $584.4M | ||
| Q1 24 | $296.5M | $401.2M |
总资产IONSRXRX
| Q4 25 | $3.5B | $1.5B | ||
| Q3 25 | $3.0B | $1.4B | ||
| Q2 25 | $3.0B | $1.3B | ||
| Q1 25 | $2.8B | $1.3B | ||
| Q4 24 | $3.0B | $1.4B | ||
| Q3 24 | $3.1B | $726.5M | ||
| Q2 24 | $2.7B | $775.9M | ||
| Q1 24 | $2.8B | $557.8M |
负债/权益比IONSRXRX
| Q4 25 | 3.71× | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | 2.13× | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-137.7M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $-159.0M | $-47.3M |
| 自由现金流率自由现金流/营收 | -78.2% | -133.1% |
| 资本支出强度资本支出/营收 | 10.5% | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-320.0M | $-378.3M |
8季度趋势，按日历期对齐
经营现金流IONSRXRX
| Q4 25 | $-137.7M | $-46.1M | ||
| Q3 25 | $-131.4M | $-117.4M | ||
| Q2 25 | $151.3M | $-76.4M | ||
| Q1 25 | $-150.8M | $-132.0M | ||
| Q4 24 | $-116.1M | $-115.4M | ||
| Q3 24 | $-115.0M | $-59.2M | ||
| Q2 24 | $-119.9M | $-82.2M | ||
| Q1 24 | $-149.9M | $-102.3M |
自由现金流IONSRXRX
| Q4 25 | $-159.0M | $-47.3M | ||
| Q3 25 | $-136.7M | $-117.6M | ||
| Q2 25 | $139.0M | $-79.6M | ||
| Q1 25 | $-163.4M | $-133.8M | ||
| Q4 24 | $-141.6M | $-116.7M | ||
| Q3 24 | $-124.0M | $-63.8M | ||
| Q2 24 | $-126.1M | $-83.4M | ||
| Q1 24 | $-154.4M | $-109.0M |
自由现金流率IONSRXRX
| Q4 25 | -78.2% | -133.1% | ||
| Q3 25 | -87.2% | -2272.5% | ||
| Q2 25 | 30.8% | -413.9% | ||
| Q1 25 | -124.1% | -907.4% | ||
| Q4 24 | -62.5% | -2567.7% | ||
| Q3 24 | -92.7% | -244.6% | ||
| Q2 24 | -56.0% | -578.5% | ||
| Q1 24 | -129.2% | -789.9% |
资本支出强度IONSRXRX
| Q4 25 | 10.5% | 3.5% | ||
| Q3 25 | 3.4% | 4.7% | ||
| Q2 25 | 2.7% | 16.4% | ||
| Q1 25 | 9.6% | 12.4% | ||
| Q4 24 | 11.3% | 28.6% | ||
| Q3 24 | 6.8% | 17.5% | ||
| Q2 24 | 2.8% | 8.2% | ||
| Q1 24 | 3.8% | 48.2% |
现金转化率IONSRXRX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.22× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IONS
| Products | $58.0M | 29% |
| Spinraza Royalties | $54.0M | 27% |
| Collaborative Agreement Revenue | $52.4M | 26% |
| Wainus Royalties | $16.0M | 8% |
| Wainua Joint Development Revenue | $9.6M | 5% |
| Other Commercial | $7.6M | 4% |
| Other Royalties | $5.7M | 3% |
RXRX
暂无分部数据
